Publications by authors named "Chi Leong Chio"
Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to further define risk stratification for CN-AML patients is worth exploring. Transcriptome data from 163 cases in the GSE12417-GPL96 dataset and 104 CN-AML patient cases in the GSE71014-GPL10558 dataset were downloaded from the Gene Expression Omnibus database for overall survival (OS) analysis and validation.
View Article and Find Full Text PDFObjectives: Previous study ( 2017; 176:498) reported that CD56 positive is associated with poor prognosis of patients with intermediate-risk acute myeloid leukemia (IR-AML). However, our data were inconsistent with the finding Thus, in this study, we provided the different results to discuss.
Methods: A total of 262 bone marrow transcriptomic data of IR-AML in the GSE12417-GPL96 and GSE71014-GPL-10558 from the Gene Expression Omnibus database (GEO) database, and 92 IR-AML patients from the cancer genome atlas (TCGA) database were obtained for prognostic analysis and validation.
Article Synopsis
- Immunotherapy using immune checkpoint inhibitors (ICIs) has improved survival rates for solid tumors, but this approach is not yet effective for acute myeloid leukemia (AML) due to limited understanding of immune checkpoint expression in AML.
- A study analyzed RNA sequencing and mutation data from 176 AML patients and validated findings with bone marrow samples from 62 patients, revealing that high levels of PD-1, PD-L1, and PD-L2 are linked to poorer overall survival.
- The research also found that specific combinations of these immune checkpoints (like PD-1/CTLA-4 and PD-L2/CTLA-4) are associated with even worse survival rates, suggesting these patterns could help in developing new therapies for AML